Samsung Electronics America and Massachusetts General Hospital (MGH) Diabetes Research Center (DRC) today jointly announced a research study to investigate the safety and efficacy of wearable devices for adults starting GLP1-RA therapy. With nearly one in five adults saying they have taken a GLP-1,[1] this innovative clinical study will investigate how data from Galaxy Watch can help patients and clinicians monitor and mitigate muscle loss - a possible side effect - by providing a clearer, more holistic view of a person's body composition and activity levels during treatment.

As GLP-1 medications become widely adopted for weight management and chronic disease treatment, tracking changes in muscle mass and physical activity alongside weight loss has emerged as a key medical focus. This research will delve into the feasibility of managing muscle loss for GLP-1 patients by utilizing biometric data including body composition, activity levels and heart rate provided by Galaxy Watch and Samsung Health.